医学部 内科学講座

釜田 康行

カマタ ヤスユキ  (Yasuyuki Kamata)

基本情報

所属
自治医科大学 医学部 内科学講座 アレルギー膠原病学部門

J-GLOBAL ID
201401043059611320
researchmap会員ID
B000237569

論文

 54
  • Ayako Kokuzawa, Jun Nakamura, Yasuyuki Kamata, Kojiro Sato
    Clinical and experimental rheumatology 41(2) 275-284 2023年3月  
    OBJECTIVES: Dermatomyositis (DM) patients with anti-melanoma differentiation-associated protein 5 (MDA5) antibodies are known for poor prognosis. This study was designed to identify humoral factors that are readily detectable in the disease and may reflect its activity and pathophysiology. METHODS: We first quantified the serum level expression of 28 cytokines in the serum of patients with collagen vascular diseases using bead-based multiplex immunoassays. We completed these evaluations at hospital admission and followed up with three DM patients with anti-MDA5 antibodies during hospitalisation. We also performed an immunohistochemical analysis of skin samples obtained from two patients. RESULTS: The serum level of interferon gamma-induced protein 10 (IP-10) was significantly higher in DM patients with anti-MDA5 antibodies than in those without the antibody, decreasing drastically upon treatment. Interestingly, this time course paralleled not that of interferon (IFN)-γ, which was originally reported to be the inducer of IP-10, but that of IFN-α2. Immunohistochemical analysis revealed that most of the IP-10-positive cells were macrophages. Furthermore, monocytes stimulated with type I IFN in vitro produced IP-10 in a dose-dependent manner. CONCLUSIONS: IP-10 is a potentially useful disease activity marker of DM with anti-MDA5 antibodies, correlating more with IFN-α2 then IFN-γ. IP-10 released from macrophages might prompt the infiltration of macrophages themselves. Thus, the type I IFN/IP-10 axis may play a pivotal role in the pathogenesis of this intractable disease.
  • Jun Nakamura, Mai Yanagida, Keisuke Saito, Yasuyuki Kamata, Takao Nagashima, Masahiro Iwamoto, Takeo Sato, Kojiro Sato
    Modern rheumatology case reports 6(2) 160-162 2022年6月24日  
    A 53-year-old woman with a 6-year history of rheumatoid arthritis (RA) presented with pharyngeal pain, fever, and altered mental status. The patient had been treated with methotrexate (MTX) 12 mg/week, baricitinib 4 mg/day, and tacrolimus 2 mg/day. Magnetic resonance imaging of the brain revealed diffuse high-intensity lesions in the cerebral white matter, basal ganglia, brainstem, and right cerebellar hemisphere. She was diagnosed with Epstein-Barr virus (EBV) encephalitis due to elevated levels of EBV-DNA in the cerebrospinal fluid and serum. Although MTX-associated lymphoproliferative disorders are well-known complications in patients with RA, EBV encephalitis requires careful attention for such patients undergoing treatment with multiple potent immunosuppressants.
  • Natsuki Shima, Ayako Kokuzawa, Keisuke Saito, Yasuyuki Kamata, Takao Nagashima, Kojiro Sato
    Internal medicine (Tokyo, Japan) 61(2) 245-248 2022年1月15日  
    A 68-year-old woman presenting with rheumatoid arthritis was admitted due to pancytopenia caused by methotrexate. Pneumocystis jirovecii pneumonia was diagnosed based on the abnormal shadows observed on chest computed tomography, the presence of serum β-D-glucan, and positive P. jirovecii-DNA results in a sputum analysis. Subsequently, after treatment with leucovorin and trimethoprim-sulfamethoxazole, lung consolidation was found to be aggravated, along with a rapidly increasing leukocyte count. In addition, cytomegalovirus colitis was diagnosed. Both conditions were associated with immune reconstitution inflammatory syndrome caused by recovery from leukopenia. The patient was successfully treated with intravenous methylprednisolone pulse therapy and ganciclovir.
  • 近藤 春香, 島 菜月, 日下 寛惟, 石澤 彩子, 釜田 康行, 長嶋 孝夫, 佐藤 浩二郎
    日本リウマチ学会関東支部学術集会プログラム・抄録集 31回 49-49 2021年12月  
  • 近藤 春香, 島 菜月, 石澤 彩子, 釜田 康行, 佐藤 浩二郎
    日本臨床免疫学会総会プログラム・抄録集 49回 107-107 2021年10月  

MISC

 13
  • Yasuyuki Kamata, Seiji Minota
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY 23(3) 172-172 2017年4月  
  • Akira Takeda, Masaki Take, Ai Hisamitsu, Kazuhiro Harada, Tokifumi Majima, Toshihiro Sugihara, Masato Okada, Yasuyuki Kamata, Seiji Minota, Akira Tanaka
    RHEUMATOLOGY 56 71-71 2017年3月  
  • Koichi Takeda, Takeo Sato, Masataro Norizuki, Yasuyuki Kamata, Katsuya Nagatani, Alan Kawarai Lefor, Seiji Minota
    RHEUMATOLOGY 54(8) 1531-1532 2015年8月  
  • Y. Akiyama, T. Sato, S. Hanai, Y. Kamata, K. Nagatani, M. Iwamoto, H. Okazaki, S. Minota
    ANNALS OF THE RHEUMATIC DISEASES 74 756-756 2015年6月  
  • 長嶋 孝夫, 室﨑 貴勝, 本根 杏子, 釜田 康行, 永谷 勝也, 岩本 雅弘, 簑田 清次
    自治医科大学紀要 = Jichi Medical University journal 38 9-16 2015年  
    Objective: To investigate the association between joint symptoms and related conditions in Japanese patientswith polymyositis( PM) and dermatomyositis( DM).Methods: We retrospectively reviewed all patients with PM/DM who were admitted to our departmentfrom January 2007 to March 2012. Clinical data on these patients were retrieved from the medical records.Results: Seventy-eight patients (20 with PM and 58 with DM) were enrolled. Among them, 37 patients(47%)had arthralgia or arthritis. Joint symptoms were more frequent in DM than PM (53% vs. 30%,P=0.07). Anti-aminoacyl tRNA antibodies (ASA) were positive in 25 patients (32%), and anti-cyclic citrullinatedpeptide (CCP)antibody was positive in 7 patients (9%). Patients with anti-Jo-1 antibody had a highfrequency of polyarthritis( 82%), while anti-CCP antibody was positive in 4 out of 11 patients with anti-Jo-1antibody (36%). Among patients with joint symptoms, anti-Jo-1 antibody was positive in 67% of the patientswith PM, but was positive in only 16% of the patients with DM. Four of the 78 patients (5%) were initiallydiagnosed and treated as having rheumatoid arthritis. Multivariate analysis showed that fever, Raynaud'sphenomenon, and anti-Jo-1 antibody were associated with joint symptoms, whereas overall ASA positivityshowed no significant difference between patients with or without joint symptoms.Conclusion: Forty-seven percent of patients with PM/DM had joint symptoms. Except for anti-Jo-1 antibody,ASA were not associated with joint symptoms in Japanese PM/DM patients.